Today: 22 March 2026
Subscribe
Browse Category

NYSE:LLY 22 October 2025 - 23 November 2025

Eli Lilly (LLY) Stock Today, November 23, 2025: Trillion‑Dollar Milestone, GLP‑1 Price War and Fresh Institutional Buying

Eli Lilly (LLY) Stock Today, November 23, 2025: Trillion‑Dollar Milestone, GLP‑1 Price War and Fresh Institutional Buying

Eli Lilly closed Friday at about $1,060 per share, briefly topping a $1 trillion market cap—the first drugmaker to do so. Institutional filings released Sunday show Coldstream Capital raised its stake by 43.5% in Q2, while Charles Schwab Investment Management increased holdings to 5.36 million shares. LLY is up over 35% year-to-date, driven by demand for its GLP-1 obesity drugs.
23 November 2025
··
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly (LLY) Stock Today, November 22, 2025: Trillion‑Dollar Milestone, New Board Member and Fresh Access Deals Fuel Momentum

Eli Lilly closed Friday, November 21, 2025, with a market value near $1 trillion, the first drugmaker to reach that mark. Shares ended around $1,060, just below their all-time high. The surge follows strong demand for its obesity and diabetes drugs, which now generate over $10 billion in quarterly sales. Year-to-date, the stock is up about 36%.
22 November 2025
··
Stocks Slip as Tech Wobble Returns; Layoffs Spike and Tariff Showdown Clouds Outlook — Stock Market Today (Nov. 6, 2025)

US Stock Market Today, November 22, 2025: Wall Street Ends a Wild Week Higher as Fed Cut Bets Rise and AI Rally Shows Cracks

The Dow Jones, S&P 500, and Nasdaq all jumped over 0.9% Friday, November 21, but still closed the week lower, with losses ranging from 1.9% to 2.7%. A shift in Federal Reserve rate-cut expectations fueled the rally after New York Fed President John Williams signaled a possible cut in December. Eli Lilly reached a $1 trillion valuation, the first for a healthcare company. US stock futures rose Friday evening.
22 November 2025
··
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly (LLY) Stock on November 15, 2025: Pricing Deal, Oral‑Obesity Pill Timeline, Q3 Beat Put Shares Near $1T — Outlook & Risks

Eli Lilly shares traded near $1,025 on Nov. 15, valuing the company just under $1 trillion. The White House announced a deal to lower Zepbound prices and expand public access, while Lilly expects FDA approval of its oral GLP‑1 pill by March 2026. Q3 revenue rose 54% to $17.6 billion. Lilly Endowment filed stock sales around the $1,000 level this month.
15 November 2025
·
Mangoceuticals (MGRX) Soars on Eli Lilly and Novo Nordisk Deal as It Launches MangoRx Direct for Obesity Drugs

Mangoceuticals (MGRX) Soars on Eli Lilly and Novo Nordisk Deal as It Launches MangoRx Direct for Obesity Drugs

Mangoceuticals announced partnerships with Eli Lilly and Novo Nordisk to offer official access to Zepbound and Wegovy through new telehealth programs, MangoRx Direct and PeachesRx Direct. Membership costs $99 per month, with GLP‑1 drugs starting at $499 monthly, no insurance required. MGRX shares jumped over 25% pre-market before retreating. The company recently settled a lawsuit with Lilly and reported a $10.3 million net loss.
13 November 2025
····
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk (NVO) Today — Nov. 12, 2025: WeightWatchers to Offer Wegovy Pill, Canada Eyes Ozempic Copies, and the Latest Stock Move

WeightWatchers plans to offer Novo Nordisk’s oral Wegovy in the U.S. after its expected 2026 launch. Sandoz says unbranded Ozempic could reach Canada by June 2026, intensifying price competition. CVS dropped Lilly’s Zepbound from its preferred list, keeping Wegovy, prompting Lilly to move employees off CVS plans. Novo Nordisk shares traded at $49.76 late Wednesday, up slightly.
12 November 2025
·····
Stocks Slip as Tech Wobble Returns; Layoffs Spike and Tariff Showdown Clouds Outlook — Stock Market Today (Nov. 6, 2025)

Stock Market Today (Nov. 11, 2025): Dow Closes at a Record as AI Shares Stumble; FTSE 100 Hits New High on BoE Cut Bets

The Dow Jones closed at a record 47,927.96 on Nov. 11, 2025, up 1.18%, while the Nasdaq fell 0.25% as Nvidia dropped nearly 3% after SoftBank revealed a $5.8 billion stake sale. The S&P 500 edged higher. In Europe, the FTSE 100 hit a record near 9,900, boosted by Vodafone’s first dividend increase in eight years and rising bets on Bank of England rate cuts.
11 November 2025
········
Eli Lilly (LLY) Pops on Fresh Deal Spree: MeiraGTx Gene Therapy Tie‑Up, New AI Collaboration, and Leerink Upgrade — Nov. 10, 2025

Eli Lilly (LLY) Pops on Fresh Deal Spree: MeiraGTx Gene Therapy Tie‑Up, New AI Collaboration, and Leerink Upgrade — Nov. 10, 2025

Eli Lilly agreed to pay $75 million upfront and over $400 million in milestones for global rights to MeiraGTx’s pediatric blindness gene therapy. The company also announced an AI drug discovery partnership with Insilico Medicine, worth over $100 million in potential payments. Leerink Partners upgraded Lilly shares and raised its price target to $1,104, sending the stock up about 5% intraday.
10 November 2025
······
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly (LLY) Pops as White House Strikes Obesity-Drug Pricing Deal; New 20% Weight‑Loss Data Fuels Momentum — Today, November 6, 2025

Eli Lilly shares rose midday, trading near $935.89, after the White House announced expanded Medicare coverage and lower prices for obesity drugs, including Zepbound. New Phase 2 data showed Lilly’s eloralintide led to up to 20.1% weight loss, with Phase 3 trials set for December 2025. BMO Capital raised its price target to $1,100.
6 November 2025
·
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk’s Weight-Loss Drug Boom Hits a Wall – Wegovy Slowdown Sparks Stock Slump and Forecast Cut

Novo Nordisk cut its 2025 sales and profit outlook for the fourth time this year after third-quarter results missed forecasts, with Wegovy revenues below expectations. Operating profit fell 30% due to restructuring costs. The company faces rising competition from Eli Lilly and U.S. copycat drugs, as well as mounting pricing pressure. Shares have dropped up to 50% in 2025; Novo plans 9,000 job cuts and a $10 billion bid for Metsera.
5 November 2025
···
Luxury Boom vs. Fed Gloom: European Markets Whipsaw (Sept 23–24, 2025)

5 Stocks You Need to Buy Now (November 4, 2025) – Tech, Energy, Biotech & More

Amazon reported record Q3 earnings with revenue up 13% year-over-year, pushing its market cap to $2.6 trillion. JPMorgan Chase beat profit estimates, posting Q3 EPS of $5.07 and trading near all-time highs. Eli Lilly’s Q3 sales jumped 54% to $17.6 billion on strong obesity drug demand. Exxon Mobil raised its dividend after record output, while Alibaba’s stock climbed on 8% sales growth and rapid AI expansion.
4 November 2025
····
Eli Lilly Stock Pre-Market Preview: Will Obesity-Drug Boom Send LLY to New Highs? (Nov 3, 2025)

Eli Lilly Stock Pre-Market Preview: Will Obesity-Drug Boom Send LLY to New Highs? (Nov 3, 2025)

Eli Lilly shares closed near $863 on Oct. 31, up about 10% for the month and close to a 52-week high. Q3 revenue jumped 54% to $17.6 billion, driven by surging demand for GLP-1 drugs Mounjaro and Zepbound, with U.S. GLP-1 market share at 57%. Management raised 2025 sales and EPS guidance sharply. The company recently won FDA approval for Inluriyo and expanded Walmart access for Zepbound.
2 November 2025
·
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly Stock on Fire: GLP-1 Bonanza, Big Earnings & AI Pivot Drive Rally

Eli Lilly reported Q3 2025 revenue of $17.60 billion, up 54% year-over-year, and raised full-year EPS guidance to $23.00–23.70. Shares closed at $813.53 on Oct. 29, down 2% over the week after hitting highs above $850 earlier in the month. The FDA approved Inluriyo for metastatic breast cancer, and the EU cleared Kisunla for early Alzheimer’s. Wall Street’s average 12-month price target stands near $939.
30 October 2025
···
Pharma Giants Converge in Frankfurt – Obesity Drug Boom & Tech Innovations Fuel $1.7 Trillion Industry Future

Pharma Giants Converge in Frankfurt – Obesity Drug Boom & Tech Innovations Fuel $1.7 Trillion Industry Future

Over 62,000 pharmaceutical professionals from more than 170 countries are attending CPHI Frankfurt 2025, where executives are meeting to address global supply chain, regulation, and innovation challenges. Eli Lilly’s GLP-1 drugs generated $6.1 billion in Q1 2025, overtaking Novo Nordisk in the U.S. weight-loss drug market. Pharma giants are investing heavily as the global obesity treatment market is projected to reach $100 billion by 2030.
28 October 2025
····
Adverum (ADVM) Stock Skyrockets on News of Lilly’s $12.47/Share Gene Therapy Deal

Adverum (ADVM) Stock Skyrockets on News of Lilly’s $12.47/Share Gene Therapy Deal

Eli Lilly said Oct. 24 it will buy Adverum Biotechnologies for $3.56 per share plus a CVR worth up to $8.91, targeting Adverum’s lead gene therapy Ixo-vec for wet AMD. Adverum shares jumped 17% on the news but stayed well below the $12.47 maximum deal value. The agreement includes a $65 million secured loan to fund trials before closing. Adverum had warned its cash would run out by Q4 2025.
24 October 2025
···
Stocks to Buy Today (Oct. 22, 2025): Top Picks as Markets Near Record Highs

Stocks to Buy Today (Oct. 22, 2025): Top Picks as Markets Near Record Highs

U.S. stock indexes hover near record highs after the Dow gained 0.5% Tuesday, while the Nasdaq slipped 0.2% on tech earnings misses. About 85% of S&P 500 companies have beaten forecasts, the highest rate in four years. AMD surged to record highs on AI chip deals, while Eli Lilly hit $935 on obesity drug demand. Netflix fell 6–7% pre-market after an earnings miss; Texas Instruments dropped nearly 9% on weak guidance.
22 October 2025
···········
1 … 8 9 10 11 12

Stock Market Today

  • Abbott Laboratories Valuation Faces Scrutiny Amid Recent Share Price Volatility
    March 22, 2026, 10:19 AM EDT. Abbott Laboratories (ABT) has experienced recent share price weakness, sparking a reassessment of its valuation. Trading at $105.46, the stock shows a 6.02% gain over 30 days but reflects mixed longer-term returns, with a 15.08% year-to-date rise against a modest 5-year total shareholder return of 5.34%. Simply Wall St's analysis estimates a fair value of $113.88, suggesting an approximate 36% intrinsic discount and potential undervaluation. Despite a P/E ratio of 28.3x above the US Medical Equipment industry average, Abbott's strong fundamentals, innovation focus, and diversified portfolio support its position as a growth stock with defensive traits. However, risks include regulatory challenges and margin pressure from costs and competition. Investors should balance these rewards and risks to inform their investment outlook on ABT.
Go toTop